Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pyramidal signs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Pyramidal signs. Displaying page 1 of 1.
    EudraCT Number: 2009-012073-34 Sponsor Protocol Number: R0000063 Start Date*: 2009-07-08
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Botulinum toxin for treating calf muscle spasticity in Hereditary Spastic Paraparesis (HSP): functional effects on dynamic balance and gait
    Medical condition: Subjects with hereditary spastic paraparesis (HSP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019903 Hereditary spastic paraplegia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002827-14 Sponsor Protocol Number: TreatSPG11 Start Date*: 2021-01-19
    Sponsor Name:IRCCS Fondazione Stella Maris
    Full Title: Phase 2 pharmacological experimental study to test the safety of miglustat in subjects with hereditary spastic paraplegia type 11
    Medical condition: Spastic paraparesis type 11 (SPG11), caused by mutations in spatacsin protein, is characterized by the association of peripheral neuropathy, parkinsonism, ataxia, cognitive impairment, hypotrophy o...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019903 Hereditary spastic paraplegia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004733-17 Sponsor Protocol Number: XAMNPEAP2019 Start Date*: 2020-02-25
    Sponsor Name:Aurora Pujol Onofre
    Full Title: Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006113-34 Sponsor Protocol Number: XAMNPIOAP2011 Start Date*: 2013-10-24
    Sponsor Name:AURORA PUJOL ONOFRE
    Full Title: Effect of pioglitazone administred to patients with Adrenomyeloneuropathy: A phase II, Singlearm, Monocentric Trial.
    Medical condition: X-linked adrenoleukodystrophy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016955-23 Sponsor Protocol Number: ASCOTALCO Start Date*: 2010-06-25
    Sponsor Name:AZIENDA USL 2 DI LUCCA
    Full Title: Assessment of association efficacy of colinergic precursor and cholinesterasic inhibitor somministered transdermal in patient with Alzheimer`s disease and severe behavioural disturbances
    Medical condition: patient with Alzheimer disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012295 Dementia of the Alzheimer's type, with delusions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-006048-42 Sponsor Protocol Number: P04628 Start Date*: 2006-09-05
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Phase 2a, Multiple-Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti-Psychotic-Induced Extra-Pyramidal Symptoms Among Subjects Wi...
    Medical condition: Patients with schizophrenia and schizoaffective disorders experiencing anti-psychotic-induced extra-pyramidal symptoms.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000472-40 Sponsor Protocol Number: CN138-169 Start Date*: 2005-08-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy w...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000698-38 Sponsor Protocol Number: MD1003CT2014-01AMN Start Date*: 2014-08-13
    Sponsor Name:MEDDAY SAS
    Full Title: MD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-003231-29 Sponsor Protocol Number: ATH434-201 Start Date*: 2022-07-26
    Sponsor Name:Alterity Therapeutics Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy
    Medical condition: Multiple System Atrophy (MSA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006224-40 Sponsor Protocol Number: AxGD Start Date*: Information not available in EudraCT
    Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka"
    Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p...
    Medical condition: Gaucher disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004731-76 Sponsor Protocol Number: LTS16004 Start Date*: 2019-12-06
    Sponsor Name:Genzyme Corporation
    Full Title: Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis
    Medical condition: Relapsing multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) SK (Completed) CZ (Completed) EE (Completed) ES (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000620-34 Sponsor Protocol Number: Imatinib-MS Start Date*: 2018-04-24
    Sponsor Name:Department of Clinical Neuroscience, Karolinska Institutet
    Full Title: Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study
    Medical condition: Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where ther...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.0 10029205 - Nervous system disorders 10028247 Multiple sclerosis like syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000894-26 Sponsor Protocol Number: BN42083 Start Date*: 2020-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL...
    Medical condition: Primary Progressive Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004494-81 Sponsor Protocol Number: PNB02-C201 Start Date*: 2012-03-29
    Sponsor Name:Pharmaneuroboost N.V.
    Full Title: Proof-of-Concept Study of Pipamperone 15mg added to Stable Treatment with Risperidone or Paliperidone in Chronic Schizophrenic and Schizoaffective Patients with Residual Symptoms: a phase I/IIa, r...
    Medical condition: Schizophrenia or Schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-R criteria.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10009134 Chronic schizophrenia LLT
    14.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004783-31 Sponsor Protocol Number: D3690C00007 Start Date*: 2007-02-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Dos...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003919-53 Sponsor Protocol Number: GN41791 Start Date*: 2020-09-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR...
    Medical condition: Primary Progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:52:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA